Table 1. Clinical and pathological characteristics and mean neuromelanin-containing cell density of donors included in the study.
| Control: Braak alpha-synuclein stage 0 | Braak alpha-synuclein stage 1–2 | Braak alpha-synuclein stage 3–4 | PD Braak alpha-synuclein stage 5–6 | ||
|---|---|---|---|---|---|
| (n = 8) | (n = 5) | (n = 7) | (n = 8) | p-value | |
| Gender | |||||
| Male, n (%) | 4 (50%) | 2 (40%) | 4 (57%) | 4 (50%) | 0.95 b |
| Female, n (%) | 4 (50%) | 3 (60%) | 3 (43%) | 4 (50%) | |
| Age of onset (SD) | NA | NA | 50 (n = 1) | 63.6 (11.2) | |
| PD duration (SD) | NA | NA | 24 (n = 1) | 17.7 (6.7) | |
| Estimated H&Y, median (range) | NA | NA | 4.0 (n = 1) | 5.0 (4.0–5.0) | |
| Demented, n (%) | NA | NA | 100% (n = 1) | 4 (50%) | |
| Age at death, y (SD) | 75.5 (7.6) | 79.4 (7.1) | 78.8(8.5) | 78.5 (8.5) | 0.81 a |
| Tangle score, median (range) | 1(0–2) | 2(0–2) | 1 (0–2) | 1 (0–2) | 0.76 b |
| Amyloid-beta score, median (range) | 0 (0-B) | A (0-B) | 0 (0-C) | A (0-C) | 0.38 b |
| Neuronal cell density, mean (standard deviation) | 6659 (960) | 5022 (930) | 4682 (1440) | 2575 (530) | <0.001 a |
Abbreviations: iLBD: incidental Lewy body disease; PD = Parkinson’s disease; H&Y = Hoehn & Yahr.
aANOVA;
bKruskal-Wallis. NA = not available